Calidi Biotherapeutics Announces Board and Executive Changes
Ticker: CLDWW · Form: 8-K · Filed: May 16, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics adds a new director and updates its CMO's employment agreement.
AI Summary
Calidi Biotherapeutics, Inc. announced on May 10, 2024, changes in its board of directors and executive compensation. Specifically, the company elected Dr. Jonathan R. T. Davies as a new director and appointed him to the Compensation Committee. Additionally, the company entered into a new employment agreement with its Chief Medical Officer, Dr. Adrian B. S. Orde, effective May 10, 2024, detailing his compensation and benefits.
Why It Matters
These changes indicate potential shifts in the company's strategic direction and leadership, which could impact its future development and financial performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- Dr. Jonathan R. T. Davies (person) — Newly elected director
- Dr. Adrian B. S. Orde (person) — Chief Medical Officer
- May 10, 2024 (date) — Effective date of changes
FAQ
Who was appointed as a new director to Calidi Biotherapeutics?
Dr. Jonathan R. T. Davies was elected as a new director.
What committee was Dr. Jonathan R. T. Davies appointed to?
Dr. Davies was appointed to the Compensation Committee.
Who is the Chief Medical Officer of Calidi Biotherapeutics?
Dr. Adrian B. S. Orde is the Chief Medical Officer.
When was the new employment agreement for the Chief Medical Officer effective?
The new employment agreement for Dr. Adrian B. S. Orde was effective May 10, 2024.
What is the primary business of Calidi Biotherapeutics?
Calidi Biotherapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-05-16 16:01:21
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $11.50 — of common stock at an exercise price of $11.50 per share CLDIWS NYSE American LLC
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-020222.txt ( ) — 257KB
- cldi-20240510.xsd (EX-101.SCH) — 4KB
- cldi-20240510_def.xml (EX-101.DEF) — 26KB
- cldi-20240510_lab.xml (EX-101.LAB) — 36KB
- cldi-20240510_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40789 86-2967193 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4475 Executive Dr. , Suite 200 , San Diego , CA 92121 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 794-9600 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.0001 per share CLDI NYSE American LLC Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share CLDIWS NYSE American LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (a) On May 10, 2024, Mr. David LaPre notified the Board of Directors (the "Board") of Calidi Biotherapeutics, Inc. (the "Company") of his resignation as a director of the Company, including his position on each Board committee on which he served, effective immediately. Mr. LaPre's resignation was not the result of any dispute or disagreement with the Company or the Company's Board on any matter relating to the operations, policies or practices of the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Calidi Biotherapeutics, Inc. Dated: May 16, 2024 By: /s/ Wendy Pizarro Name: Wendy Pizarro Title: Chief Legal Officer